Volunteers wanted to try a new treatment for asthma
The Prevenar study is testing whether Pneumonia vaccine can reduce airway inflammation and improve daily asthma symptoms.
Conducted by a team of researchers from the John Hunter Hospital and the University of Newcastle, this study will investigate the role of a Pneumoccocal vaccine in the treatment of asthma.
Led by Professor Peter Gibson and Professor Phil Hansbro, the trial will explore whether the pneumococcal vaccine has a beneficial effect on asthma outcomes.
The study will compare two pneumococcal vaccines – Prevenar13 and Pneumovax23 to see whether the administration of Prevenar can reduce airway inflammation as well as whether it improves daily symptoms.
To participate in the study, the researchers are looking for people over the age of 18 who have a diagnosis of asthma.
Participants will be required to attend the Respiratory Department Clinical Trial Centre at the Hunter Medical Research Institute (HMRI).
The study will require five visits over the course of the year.
Participants will not need to stop their daily medication and their asthma will be closely monitored.
To find out more, contact Catherine Delahunty on email: Catherine.Delahunty@newcastle.edu.au or phone 02 4042 0135.